COMMUNIQUÉS West-GlobeNewswire

Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025
31/07/2025
ASHBURN, Va., July 31, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
InspireMD Announces Combined Financings of $58 Million
31/07/2025
Proceeds Bolster Balance Sheet to Commercialize Recently FDA Approved Best-In-Class Carotid Stent MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the [...]
Clover Health Applauds White House and CMS’ Push to “Tear Down Digital Walls,” Accelerating and Simplifying Access to Health Data for Patients and Their Clinicians
31/07/2025
Clover Health’s AI platform, Counterpart Assistant, already connects to a majority of the data networks named in yesterday’s pledge – eliminating the “digital walls,” delivering proven outcomes in chronic disease care, [...]
Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial
31/07/2025
Strategic CRO Partnership Supports Operational Readiness and Initiation of Upcoming Concussion Study SARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage [...]
NetraMark to Attend Canaccord Genuity’s 45th Annual Growth Conference
31/07/2025
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials [...]
STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update
31/07/2025
HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Profusa Secures Lumee™ Oxygen Platform Distributor in Spain
31/07/2025
BERKELEY, Calif, July 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (NASDAQ: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the [...]
Vericel Reports Second Quarter 2025 Financial Results
31/07/2025
Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted [...]
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
31/07/2025
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc ., (Nasdaq: MXCT), a [...]
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
31/07/2025
Akebia to Host Conference Call on August 7, 2025, at 8:00 a.m. EDT CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results [...]
Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award
31/07/2025
GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief [...]
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
31/07/2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will [...]
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7
31/07/2025
DUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a [...]
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
31/07/2025
SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second [...]
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
31/07/2025
BASKING RIDGE, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]
Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms
31/07/2025
Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Onco-Innovations Limited (CBOE CA: ONCO ) (OTCQB: ONNVF ) ( [...]
VedTechBio Unveils Next-Gen Drug Discovery AI; Partners with AlphaMeld in Multi-Therapy Collaboration
31/07/2025
BENGALURU, India, July 31, 2025 (GLOBE NEWSWIRE) -- VedTechBio Research Pvt. Ltd., a pioneer in AI-driven drug discovery, today announced major enhancements to its RxAgentAI™ platform, cutting drug discovery timelines [...]
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
31/07/2025
Available data from 13 patients with recurrent, platinum resistant, ARID1a-mutated ovarian cancer treated with 75 mg/day in the NXP800 Phase 1b study includes 2 partial responses and 3 stable diseases; thrombocytopenia [...]
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
31/07/2025
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring Deep Experience in [...]

Pages